Founded 2016. University-affiliated early-stage VC via AlbionVC partnership. Fund I made 45 investments (27 spinouts, 2 NASDAQ IPOs: Orchard Therapeutics, MeiraGTx; portfolio raised £1bn+ externally, 570+ jobs). Fund II targeted £100m first close. ~35–40 active portfolio companies. Team: 12 members (2 partners, 3 VPs, 2 principals). HQ: London.
Investment Focus
Investment Thesis
UCL spinouts only. Seed-stage & Series A across life sciences (gene therapy, therapeutics, biotech), physical sciences (photonics, materials, AI hardware), digital health. Check sizes £250k–£7m (seed to spinout). Proof-of-concept funding up to £250k; licensing projects £500k–£2m; spinout equity up to £7m total. Avoids non-UCL IP. Managed by AlbionVC + UCL Business (UCLB).
Interested in connecting?
Visit their website or reach out directly.